Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 63

1.

Vitamin D and MRI measures in progressive multiple sclerosis.

Abbatemarco JR, Fox RJ, Li H, Ontaneda D.

Mult Scler Relat Disord. 2019 Aug 13;35:276-282. doi: 10.1016/j.msard.2019.08.014. [Epub ahead of print]

PMID:
31445221
2.

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis.

Dutta R, Mahajan KR, Nakamura K, Ontaneda D, Chen J, Volsko C, Dudman J, Christie E, Dunham J, Fox RJ, Trapp BD.

J Vis Exp. 2019 Jul 19;(149). doi: 10.3791/59511.

PMID:
31380830
3.

Early highly effective versus escalation treatment approaches in relapsing multiple sclerosis.

Ontaneda D, Tallantyre E, Kalincik T, Planchon SM, Evangelou N.

Lancet Neurol. 2019 Jul 30. pii: S1474-4422(19)30151-6. doi: 10.1016/S1474-4422(19)30151-6. [Epub ahead of print] Review.

PMID:
31375366
4.

Diagnosis and Management of Progressive Multiple Sclerosis.

Macaron G, Ontaneda D.

Biomedicines. 2019 Jul 29;7(3). pii: E56. doi: 10.3390/biomedicines7030056. Review.

5.

Exploratory MRI measures after intravenous autologous culture-expanded mesenchymal stem cell transplantation in multiple sclerosis.

Feng J, Offerman E, Lin J, Fisher E, Planchon SM, Sakaie K, Lowe M, Nakamura K, Cohen JA, Ontaneda D.

Mult Scler J Exp Transl Clin. 2019 Jun 14;5(2):2055217319856035. doi: 10.1177/2055217319856035. eCollection 2019 Apr-Jun.

6.

Progressive Multiple Sclerosis.

Ontaneda D.

Continuum (Minneap Minn). 2019 Jun;25(3):736-752. doi: 10.1212/CON.0000000000000727.

PMID:
31162314
7.

MOG-related disorders: A new cause of imaging-negative myelitis?

Macaron G, Ontaneda D.

Mult Scler. 2019 Apr 1:1352458519840746. doi: 10.1177/1352458519840746. [Epub ahead of print]

PMID:
30931813
8.

Imaging outcome measures of neuroprotection and repair in MS: A consensus statement from NAIMS.

Oh J, Ontaneda D, Azevedo C, Klawiter EC, Absinta M, Arnold DL, Bakshi R, Calabresi PA, Crainiceanu C, Dewey B, Freeman L, Gauthier S, Henry R, Inglese M, Kolind S, Li DKB, Mainero C, Menon RS, Nair G, Narayanan S, Nelson F, Pelletier D, Rauscher A, Rooney W, Sati P, Schwartz D, Shinohara RT, Tagge I, Traboulsee A, Wang Y, Yoo Y, Yousry T, Zhang Y, Sicotte NL, Reich DS; North American Imaging in Multiple Sclerosis Cooperative.

Neurology. 2019 Mar 12;92(11):519-533. doi: 10.1212/WNL.0000000000007099. Epub 2019 Feb 20. Review. Erratum in: Neurology. 2019 Jul 2;93(1):46.

PMID:
30787160
9.

MS progression is predominantly driven by age-related mechanisms - NO.

McGinley M, Ontaneda D.

Mult Scler. 2019 Jun;25(7):904-906. doi: 10.1177/1352458518819712. Epub 2019 Feb 12. No abstract available.

PMID:
30747571
10.

Multiple sclerosis risk factors contribute to onset heterogeneity.

Briggs FBS, Yu JC, Davis MF, Jiangyang J, Fu S, Parrotta E, Gunzler DD, Ontaneda D.

Mult Scler Relat Disord. 2019 Feb;28:11-16. doi: 10.1016/j.msard.2018.12.007. Epub 2018 Dec 4.

PMID:
30529925
11.

Clinical commentary on "Warts and all: Fingolimod and unusual HPV associated lesions".

Macaron G, Ontaneda D.

Mult Scler. 2018 Nov 14:1352458518813109. doi: 10.1177/1352458518813109. [Epub ahead of print] No abstract available.

PMID:
30427261
12.

Comparative effectiveness of dimethyl fumarate versus fingolimod and teriflunomide among MS patients switching from first-generation platform therapies in the US.

Ontaneda D, Nicholas J, Carraro M, Zhou J, Hou Q, Babb J, Riester K, Mendoza JP, Livingston T, Jhaveri M.

Mult Scler Relat Disord. 2019 Jan;27:101-111. doi: 10.1016/j.msard.2018.09.038. Epub 2018 Oct 10.

13.

Treatment decisions in MS: Shifting the goal posts or changing how we see them?

Mahajan KR, Nakamura K, Ontaneda D.

Mult Scler. 2018 Oct;24(12):1523-1525. doi: 10.1177/1352458518801479. Epub 2018 Sep 20. No abstract available.

PMID:
30234433
14.

Identifying a new subtype of multiple sclerosis.

Trapp BD, Ontaneda D.

Neurodegener Dis Manag. 2018 Dec;8(6):367-369. doi: 10.2217/nmt-2018-0032. Epub 2018 Sep 14.

15.

Automated Integration of Multimodal MRI for the Probabilistic Detection of the Central Vein Sign in White Matter Lesions.

Dworkin JD, Sati P, Solomon A, Pham DL, Watts R, Martin ML, Ontaneda D, Schindler MK, Reich DS, Shinohara RT.

AJNR Am J Neuroradiol. 2018 Oct;39(10):1806-1813. doi: 10.3174/ajnr.A5765. Epub 2018 Sep 13.

16.

Phase 2 Trial of Ibudilast in Progressive Multiple Sclerosis.

Fox RJ, Coffey CS, Conwit R, Cudkowicz ME, Gleason T, Goodman A, Klawiter EC, Matsuda K, McGovern M, Naismith RT, Ashokkumar A, Barnes J, Ecklund D, Klingner E, Koepp M, Long JD, Natarajan S, Thornell B, Yankey J, Bermel RA, Debbins JP, Huang X, Jagodnik P, Lowe MJ, Nakamura K, Narayanan S, Sakaie KE, Thoomukuntla B, Zhou X, Krieger S, Alvarez E, Apperson M, Bashir K, Cohen BA, Coyle PK, Delgado S, Dewitt LD, Flores A, Giesser BS, Goldman MD, Jubelt B, Lava N, Lynch SG, Moses H, Ontaneda D, Perumal JS, Racke M, Repovic P, Riley CS, Severson C, Shinnar S, Suski V, Weinstock-Guttman B, Yadav V, Zabeti A; NN102/SPRINT-MS Trial Investigators.

N Engl J Med. 2018 Aug 30;379(9):846-855. doi: 10.1056/NEJMoa1803583.

17.

Cortical neuronal densities and cerebral white matter demyelination in multiple sclerosis: a retrospective study.

Trapp BD, Vignos M, Dudman J, Chang A, Fisher E, Staugaitis SM, Battapady H, Mork S, Ontaneda D, Jones SE, Fox RJ, Chen J, Nakamura K, Rudick RA.

Lancet Neurol. 2018 Oct;17(10):870-884. doi: 10.1016/S1474-4422(18)30245-X. Epub 2018 Aug 22.

PMID:
30143361
18.

Discontinuation and comparative effectiveness of dimethyl fumarate and fingolimod in 2 centers.

Vollmer B, Ontaneda D, Bandyopadhyay A, Cohn S, Nair K, Sillau S, Bermel RA, Corboy JR, Fox RJ, Vollmer T, Cohen JA, Alvarez E, Hersh CM.

Neurol Clin Pract. 2018 Aug;8(4):292-301. doi: 10.1212/CPJ.0000000000000487.

19.

Stem cell injection-induced glioneuronal lesion of the cauda equina.

Lee BS, Achey RL, Yeaney GA, Bosler DS, Aly Z, Ontaneda D, Morren J, Benzel EC.

Neurology. 2018 Mar 27;90(13):613-615. doi: 10.1212/WNL.0000000000005219. Epub 2018 Feb 23. No abstract available.

PMID:
29476035
20.

Clinical outcome measures for progressive MS trials.

Ontaneda D, Cohen JA, Amato MP.

Mult Scler. 2017 Oct;23(12):1627-1635. doi: 10.1177/1352458517729465. Review.

PMID:
29041863
21.

The challenges and opportunities of multiple sclerosis care in Latin America.

Ontaneda D, Correale J.

Mult Scler J Exp Transl Clin. 2017 Sep 25;3(3):2055217317720845. doi: 10.1177/2055217317720845. eCollection 2017 Jul-Sep. No abstract available.

22.

Comparative efficacy and discontinuation of dimethyl fumarate and fingolimod in clinical practice at 24-month follow-up.

Hersh CM, Love TE, Bandyopadhyay A, Cohn S, Hara-Cleaver C, Bermel RA, Fox RJ, Cohen JA, Ontaneda D.

Mult Scler J Exp Transl Clin. 2017 Aug 24;3(3):2055217317715485. doi: 10.1177/2055217317715485. eCollection 2017 Jul-Sep.

23.

T1-/T2-weighted ratio differs in demyelinated cortex in multiple sclerosis.

Nakamura K, Chen JT, Ontaneda D, Fox RJ, Trapp BD.

Ann Neurol. 2017 Oct;82(4):635-639. doi: 10.1002/ana.25019. Epub 2017 Sep 21.

PMID:
28833377
24.

Diagnostic performance of central vein sign for multiple sclerosis with a simplified three-lesion algorithm.

Solomon AJ, Watts R, Ontaneda D, Absinta M, Sati P, Reich DS.

Mult Scler. 2018 May;24(6):750-757. doi: 10.1177/1352458517726383. Epub 2017 Aug 18.

25.

The Role of Advanced Magnetic Resonance Imaging Techniques in Multiple Sclerosis Clinical Trials.

Mahajan KR, Ontaneda D.

Neurotherapeutics. 2017 Oct;14(4):905-923. doi: 10.1007/s13311-017-0561-8. Review.

26.

Treating primary-progressive multiple sclerosis: potential of ocrelizumab and review of B-cell therapies.

Feng JJ, Ontaneda D.

Degener Neurol Neuromuscul Dis. 2017 Feb 1;7:31-45. doi: 10.2147/DNND.S100096. eCollection 2017. Review.

27.

Smokers with MS have greater decrements in quality of life and disability than non-smokers.

Briggs FB, Gunzler DD, Ontaneda D, Marrie RA.

Mult Scler. 2017 Nov;23(13):1772-1781. doi: 10.1177/1352458516685169. Epub 2017 Jan 6.

28.

Comparative efficacy and discontinuation of dimethyl fumarate and fingolimod in clinical practice at 12-month follow-up.

Hersh CM, Love TE, Cohn S, Hara-Cleaver C, Bermel RA, Fox RJ, Cohen JA, Ontaneda D.

Mult Scler Relat Disord. 2016 Nov;10:44-52. doi: 10.1016/j.msard.2016.08.002. Epub 2016 Aug 8.

PMID:
27919497
29.

Progressive multiple sclerosis: prospects for disease therapy, repair, and restoration of function.

Ontaneda D, Thompson AJ, Fox RJ, Cohen JA.

Lancet. 2017 Apr 1;389(10076):1357-1366. doi: 10.1016/S0140-6736(16)31320-4. Epub 2016 Nov 24. Review.

PMID:
27889191
30.

The central vein sign and its clinical evaluation for the diagnosis of multiple sclerosis: a consensus statement from the North American Imaging in Multiple Sclerosis Cooperative.

Sati P, Oh J, Constable RT, Evangelou N, Guttmann CR, Henry RG, Klawiter EC, Mainero C, Massacesi L, McFarland H, Nelson F, Ontaneda D, Rauscher A, Rooney WD, Samaraweera AP, Shinohara RT, Sobel RA, Solomon AJ, Treaba CA, Wuerfel J, Zivadinov R, Sicotte NL, Pelletier D, Reich DS; NAIMS Cooperative.

Nat Rev Neurol. 2016 Dec;12(12):714-722. doi: 10.1038/nrneurol.2016.166. Epub 2016 Nov 11. Review.

PMID:
27834394
31.

Inadequate outcome measures are the biggest impediment to successful clinical trials in progressive MS - Commentary.

Ontaneda D.

Mult Scler. 2017 Apr;23(4):508-509. doi: 10.1177/1352458516674368. Epub 2016 Oct 11. No abstract available.

PMID:
27729553
32.

Imaging as an Outcome Measure in Multiple Sclerosis.

Ontaneda D, Fox RJ.

Neurotherapeutics. 2017 Jan;14(1):24-34. doi: 10.1007/s13311-016-0479-6. Review.

33.

Measuring Brain Tissue Integrity during 4 Years Using Diffusion Tensor Imaging.

Ontaneda D, Sakaie K, Lin J, Wang XF, Lowe MJ, Phillips MD, Fox RJ.

AJNR Am J Neuroradiol. 2017 Jan;38(1):31-38. doi: 10.3174/ajnr.A4946. Epub 2016 Sep 22.

34.

Heterogeneous depression trajectories in multiple sclerosis patients.

Gunzler DD, Morris N, Perzynski A, Ontaneda D, Briggs F, Miller D, Bermel RA.

Mult Scler Relat Disord. 2016 Sep;9:163-9. doi: 10.1016/j.msard.2016.08.004. Epub 2016 Aug 5.

35.

Natalizumab-related PML 2 weeks after negative anti-JCV antibody assay.

Ontaneda D, Fox RJ, Gagne Brosseau MS, Stobbe G, Wundes A.

Neurology. 2016 Aug 30;87(9):957-8. doi: 10.1212/WNL.0000000000003081. No abstract available.

PMID:
27572430
36.

Design, rationale, and baseline characteristics of the randomized double-blind phase II clinical trial of ibudilast in progressive multiple sclerosis.

Fox RJ, Coffey CS, Cudkowicz ME, Gleason T, Goodman A, Klawiter EC, Matsuda K, McGovern M, Conwit R, Naismith R, Ashokkumar A, Bermel R, Ecklund D, Koepp M, Long J, Natarajan S, Ramachandran S, Skaramagas T, Thornell B, Yankey J, Agius M, Bashir K, Cohen B, Coyle P, Delgado S, Dewitt D, Flores A, Giesser B, Goldman M, Jubelt B, Lava N, Lynch S, Miravalle A, Moses H, Ontaneda D, Perumal J, Racke M, Repovic P, Riley C, Severson C, Shinnar S, Suski V, Weinstock-Gutman B, Yadav V, Zabeti A.

Contemp Clin Trials. 2016 Sep;50:166-77. doi: 10.1016/j.cct.2016.08.009. Epub 2016 Aug 10.

37.

Relapse rates in patients with multiple sclerosis treated with fingolimod: Subgroup analyses of pooled data from three phase 3 trials.

Derfuss T, Ontaneda D, Nicholas J, Meng X, Hawker K.

Mult Scler Relat Disord. 2016 Jul;8:124-30. doi: 10.1016/j.msard.2016.05.015. Epub 2016 May 24.

38.

Propensity methods for multiple sclerosis: The devil is in the details.

Ontaneda D, Love TE.

Mult Scler. 2016 Sep;22(10):1248-9. doi: 10.1177/1352458516660390. Epub 2016 Jul 13. No abstract available.

PMID:
27411702
39.

Camptocormia and Pisa syndrome as manifestations of acute myasthenia gravis exacerbation.

Abboud H, Sivaraman I, Ontaneda D, Tavee J.

J Neurol Sci. 2015 Dec 15;359(1-2):8-10. doi: 10.1016/j.jns.2015.10.020. Epub 2015 Oct 19. No abstract available.

PMID:
26671078
40.

Risk Mitigation Strategies for Adverse Reactions Associated with the Disease-Modifying Drugs in Multiple Sclerosis.

Subei AM, Ontaneda D.

CNS Drugs. 2015 Sep;29(9):759-71. doi: 10.1007/s40263-015-0277-4. Review.

41.

Progressive multiple sclerosis.

Ontaneda D, Fox RJ.

Curr Opin Neurol. 2015 Jun;28(3):237-43. doi: 10.1097/WCO.0000000000000195. Review.

42.

Clinical trials in progressive multiple sclerosis: lessons learned and future perspectives.

Ontaneda D, Fox RJ, Chataway J.

Lancet Neurol. 2015 Feb;14(2):208-23. doi: 10.1016/S1474-4422(14)70264-9. Review.

43.

Identifying the start of multiple sclerosis injury: a serial DTI study.

Ontaneda D, Sakaie K, Lin J, Wang X, Lowe MJ, Phillips MD, Fox RJ.

J Neuroimaging. 2014 Nov-Dec;24(6):569-576. doi: 10.1111/jon.12082. Epub 2014 Feb 23.

44.

Experience with fingolimod in clinical practice.

Hersh CM, Hara-Cleaver C, Rudick RA, Cohen JA, Bermel RA, Ontaneda D.

Int J Neurosci. 2015;125(9):678-85. doi: 10.3109/00207454.2014.969839. Epub 2014 Oct 29.

45.

Risk stratification and mitigation multiple sclerosis.

Ontaneda D, Cohn S, Fox R.

Mult Scler Relat Disord. 2014 Sep;3(5):639-49. Review.

46.

Sensitivity to volatile anesthetics in patients with dementia: a case-control analysis.

Perez-Protto S, Geube M, Ontaneda D, Dalton JE, Kurz A, Sessler DI.

Can J Anaesth. 2014 Jul;61(7):611-8. doi: 10.1007/s12630-014-0165-2. Epub 2014 Apr 25.

PMID:
24764187
47.

Diffusion tensor imaging before, during and after progressive multifocal leukoencephalopathy.

Ontaneda D, Sakaie K, Lin J, Lowe MJ, Phillips MD, Fox RJ.

Eur J Neurol. 2014 Apr;21(4):e36-8. doi: 10.1111/ene.12361. No abstract available.

PMID:
24628903
48.

Is neuromyelitis optica with advanced age of onset a paraneoplastic disorder?

Ontaneda D, Fox RJ.

Int J Neurosci. 2014 Jul;124(7):509-11. doi: 10.3109/00207454.2013.854208. Epub 2013 Oct 31.

49.

Multiple sclerosis treatment: risk mitigation.

Ontaneda D, Fox RJ.

Continuum (Minneap Minn). 2013 Aug;19(4 Multiple Sclerosis):1092-9. doi: 10.1212/01.CON.0000433280.10523.f0.

PMID:
23917104
50.

The benefits and risks of alemtuzumab in multiple sclerosis.

Ontaneda D, Cohen JA.

Expert Rev Clin Immunol. 2013 Mar;9(3):189-91. doi: 10.1586/eci.13.1. No abstract available.

PMID:
23445192

Supplemental Content

Loading ...
Support Center